<DOC>
	<DOCNO>NCT01032915</DOCNO>
	<brief_summary>This study ass safety efficacy AIN457 adjunctive therapy treatment intermediate uveitis , posterior uveitis , panuveitis require systemic immunosuppression .</brief_summary>
	<brief_title>Safety Efficacy AIN457 Patients With Quiescent Non-infectious Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Patients quiescent chronic , noninfectious intermediate uveitis , posterior uveitis panuveitis evidence &lt; 1+ anterior chamber cell grade &lt; 1+ vitreous haze eye least 6 week prior screen . Requirement either follow immunosuppressive therapy time within past 3 month treatment prevention uveitis must increase within 6 week prior screen : Prednisone equivalent ≥10 mg daily . ≥1 periocular injection ≥1 intravitreal corticosteroid injection ( i.e . triamcinolone ) study eye within past 6 month ( last injection must give 6 week prior screen . ) Treatment either cyclosporine , tacrolimus , azathioprine , mycophenolate mofetil , mycophenolic acid , methotrexate monotherapy combination without steroid . ( Patients treat chlorambucil cyclophosphamide within past 5 year ineligible study . ) Patients meet specify criterion immunosuppressive therapy eligible enrollment intolerant systemic immunosuppressive therapy determine study investigator . Ocular concomitant conditions/disease Patients primary diagnosis Behcet 's disease , anterior uveitis intermediate uveitis , posterior uveitis panuveitis manifestation ( ) active intraocular inflammatory disease may spontaneously resolve characterize presence either anterior chamber cell vitritis ( vitreous cell haze ) white dot retinochoroidopathies ( i.e . Punctate inner choroidopathy ( PIC ) , acute zonal occult outer retinopathy ( AZOOR . ) Patients active , noninfectious intermediate , posterior panuveitis one eye ( ≥1+ anterior chamber cell /or ≥1+ vitreous haze . ) Patients receive may require corticosteroid ( prednisone equivalent ) ≥1 mg/kg/day maintain quiescence intraocular inflammation . Ocular treatment Treatment intravitreal antiVEGF agent administer study eye within 3 month prior screen . Treatment fluocinolone acetonide implant ( Retisert® ) study eye within last 3 year , dexamethasone intravitreal implant investigational corticosteroid implant study eye within last 6 month . Intraocular surgery laser photocoagulation study eye within last 6 week prior screen except diagnostic vitreous aqueous tap smallgauge needle . Systemic condition treatment Any systemic biologic therapy ( e.g . interferon , infliximab , daclizumab , etanercept , adalimumab ) give intravenously subcutaneously within 3 month prior screen . No biologic therapy investigational study treatment allow course clinical trial . Any prior treatment systemic alkylating agent ( cyclophosphamide , chlorambucil ) within past 5 year prior screen . Treatment live liveattenuated vaccine ( include vaccine varicellazoster measles ) within 2 month prior screen . No treatment live liveattenuated vaccine allow course clinical trial . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Quiescent uveitis</keyword>
	<keyword>intermediate uveitis</keyword>
	<keyword>panuveitis</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>uveitis</keyword>
</DOC>